The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1269-1277

  Marso, Steven P ^a,b   Ellis, Stephen G ^b   Tuzcu, E Murat ^a   Whitlow, Patrick L ^b   Franco, Irving ^a   Raymond, Russell E ^a   Topol, Eric J ^b  

^a Cleveland Clinic Foundation ^*

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; TRANSLUMINAL CORONARY ANGIOPLASTY; URINALYSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CREATININE; DEATH, SUDDEN, CARDIAC; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OHIO; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; RISK FACTORS; SURVIVAL RATE;

EID: 0033117210     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00035-2     Document Type: Article

References (33)

1. Harris MI, Hadden WC, Knowler WC, Bennet PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987;36:523-34.
2. Schwartz CJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992;15:1156-67.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
4. Wingard DL, Barrett-Conner E. Heart Disease and Diabetes. Diabetes in America. Vol. NIH publication n. 95-1468. Washington, DC: US Department of Health and Human Services, 1995:429-48.
5. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
6. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry [see comments]. Circulation 1996;94:1818-25.
7. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25.
8. Abdel-Meguid AE, Whitlow PL, Simpfendorfer C, et al. Percutaneous revascularization of ostial saphenous vein graft stenoses. J Am Coll Cardiol 1995;26:955-60.
9. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) [see comments]. Circulation 1997;96:1761-9.
10. Mogensen CE, Damsgaard EM, Froland A, Nielsen S, de Fine Olivarius N, Schmitz A. Microalbuminuria in noninsulin dependent diabetes. Clin Nephrol 1992;38:528-38.
11. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetic Med 1995;12:149-55.
12. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in noninsulin-dependent diabetics. Diabetic Med 1984;1:17-9.
13. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
14. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. Arch Int Med 1997;157:1413-8.
15. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabetic Medicine 1988;5:126-34.
16. Stiegler H, Standl E, Schulz K, Roth R, Lehmacher W. Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabetic Med 1992;9:646-53.
17. Patrick AW, Leslie PJ, Clarke BF, Frier BM. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis. Diabetic Med 1990;7: 902-8.
18. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in noninsulin-dependent diabetes mellitus. Lancet 1992;340:319-23.
19. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736-41.
20. Niskanen L, Voutilainen R, Terasvirta M, et al. A prospective study of clinical and metabolic associates of proteinuria in patients with type 2 diabetes mellitus. Diabetic Med 1993;10: 543-9.
21. Standl E, Stiegler H. Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the greater Munich area. Diabetologia 1993;36:1017-20.
22. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993;16:996-1003.
23. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995;38:610-6.
24. Beatty OL, Ritchie CM, Bell PM, Hadden DR, Kennedy L, Atkinson AB. Microalbuminuria as identified by a spot morning urine specimen in non-insulin-treated diabetes: an eight-year follow-up study. Diabetic Med 1995;12:261-6.
25. NHLI BARI clinical alert on diabetics treated with angioplasty. Circulation 1995;92.
26. Zimmet PZ, Alberti KG. The changing face of macrovascular disease in non-insulin dependent diabetes mellitus: an epidemic in progress. Lancet 1997;350 Suppl:SI1-4.
27. Cooper ME. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. J Hypertens 1996;14 Suppl:S11-4.
28. Donnelly R, Molyneaux LM, Willey KA, Yue DK. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol 1996;77:26B-30B.
29. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Int Med 1993;153:2426-35.
30. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995;99:497-504.
31. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [see comments] [published erratum appears in N Engl J Med 1993 Jan 13;330(2):152]. N Engl J Med 1993;329:1456-62.
32. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients [see comments]. Ann Int Med 1993;118:577-81.
33. Passa P, Chatellier G. The DIAB-HYCAR Study. Diabetologia 1996;39:1662-7.